The Effect of Intravenous Autologous Activated Platelet-Rich Plasma Therapy on “Profibrotic Cytokine” IL-1<i>β</i> Levels in Severe and Critical COVID-19 Patients: A Preliminary Study

<div>Patients’ PaO<sub>2</sub>/FiO<sub>2</sub> ratio after aaPRP administration.</div>

Scientifica

fig3

Figure 3

Figure 3: The Effect of Intravenous Autologous Activated Platelet-Rich Plasma Therapy on “Profibrotic Cytokine” IL-1<i>β</i> Levels in Severe and Critical COVID-19 Patients: A Preliminary Study 

Figure 3 | The Effect of Intravenous Autologous Activated Platelet-Rich Plasma Therapy on “Profibrotic Cytokine” IL-1β Levels in Severe and Critical COVID-19 Patients: A Preliminary Study 